23 Aug Exact Sciences’ stock soars on news that Pfizer will market Cologuard test
Exact Sciences Corp. stock leaped more than 30 percent Wednesday after the Madison company announced that drug giant Pfizer will help sell Exact’s Cologuard non-invasive DNA stool test for colorectal cancer. Pfizer will invest $20 million to $24 million a year, for a total of more...